Loading...
Please wait, while we are loading the content...
Similar Documents
Development of Anti-TNFR Antibody-Conjugated Nanoparticles
| Content Provider | MDPI |
|---|---|
| Author | Aido, Ahmed Wajant, Harald Buzgo, Matej Simaite, Aiva |
| Copyright Year | 2020 |
| Description | Immunotherapy is considered as a new pillar of cancer treatment. However, the application of some promising immunotherapeutic antibodies, such as antibodies against certain immune-stimulatory receptors of the TNF receptor superfamily (TNFRs), including CD40, 41BB, CD27 and anti-fibroblast growth factor-inducible 14 (anti-Fn14), are limited due to their low bioactivity. It has been previously shown that the bioactivity of such anti-TNFR antibodies could be improved by crosslinking or attachment to the plasma membrane by interaction with Fcγ receptors (FcγR). Both result in the proximity of multiple antibody-bound TNFR molecules, which allow for the activation of proinflammatory signaling pathways. In this work, we have grafted antibodies on gold nanoparticles to simulate the “activating” effect of FcγR-bound, and thus plasma membrane-presented anti-TNFR antibodies. We have developed and optimized the method for the preparation of gold nanoparticles, their functionalization with poly-ethylene glycol (PEG) linkers, and grafting of antibodies on the surface. We showed here that antibodies, including the anti-Fn14 antibody PDL192, can be successfully attached to nanoparticles without affecting antigen binding. We hypothesize that conjugation of monoclonal anti-TNFR antibodies to the inorganic nanoparticles is a promising technique to boost the efficacy of these immunotherapeutic antibodies. |
| Starting Page | 55 |
| e-ISSN | 25043900 |
| DOI | 10.3390/IECP2020-08684 |
| Journal | Proceedings |
| Issue Number | 1 |
| Volume Number | 78 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2020-12-01 |
| Access Restriction | Open |
| Subject Keyword | Proceedings Biochemical Research Nanoparticles Surface Modification Drug-delivery Agonistic Anti Tnfrsf Receptor (tnfr) Antibody |
| Content Type | Text |